Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 14/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.51 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5664378 | 0.90 | ROCK2 (0.61) | ROCK2ROCK1PRKCZCCR2TRPV1 | |
| SCHEMBL5664368 | 0.90 | ROCK2 (0.61) | ROCK2ROCK1PRKCZCCR2TRPV1 | |
| SCHEMBL5665109 | 0.90 | ROCK2 (0.61) | ROCK2ROCK1PRKCZCCR2TRPV1 | |
| SCHEMBL5662650 | 0.83 | PRKD3 (0.43) | ROCK2ROCK1PRKCZBTKPIM1 | |
| SCHEMBL4477690 | 0.78 | ROCK2 (0.56) | ROCK2ROCK1CCR2 | |
| SCHEMBL5661736 | 0.78 | HCRTR1 (0.46) | ROCK2ROCK1TRPV1 | |
| SCHEMBL5661731 | 0.78 | HCRTR1 (0.46) | ROCK2ROCK1TRPV1 | |
| SCHEMBL5662572 | 0.78 | ROCK2 (0.58) | ROCK2ROCK1CCR2 | |
| SCHEMBL29862650 | 0.78 | ROCK2 (0.58) | ROCK2ROCK1CCR2 | |
| SCHEMBL3246360 | 0.77 | TRPV1 (0.63) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7094789-B2 | 5-substituted isoquinoline derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-08-22 | — | — | US | disclosed |
| EP-1541559-A1 | 5-SUBSTITUTED ISOQUINOLINE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20050020623-A1 | 5-Substituted isoquinoline derivatives | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020623-A1 | 5-Substituted isoquinoline derivatives | MYLK, MYLK2, MYL12A | ROCK2 158/4885ROCK1 75/4885PRKCZ 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.